StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Nektar Therapeutics's profit margin for the twelve months ending Dec 31, 2025 was -297.1%. For fiscal 2025 it was -297.1%, against -120.9% the year before. The highest annual figure on record is 57.1% in fiscal 2018.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-297.1%−176.2
FY2024Dec 31, 2024-120.9%+185.5
FY2023Dec 31, 2023-306.3%+93.7
FY2022Dec 31, 2022-400.0%+114.1
FY2021Dec 31, 2021-514.0%−223.4
FY2020Dec 31, 2020-290.6%+93.8
FY2019Dec 31, 2019-384.5%−441.6
FY2018Dec 31, 201857.1%+88.5
FY2017Dec 31, 2017-31.4%+61.4
FY2016Dec 31, 2016-92.8%−57.6
FY2015Dec 31, 2015-35.2%−8.3
FY2014Dec 31, 2014-26.9%+81.9
FY2013Dec 31, 2013-108.8%+102.9
FY2012Dec 31, 2012-211.7%−24.2
FY2011Dec 31, 2011-187.4%−163.6
FY2010Dec 31, 2010-23.9%+118.7
FY2009Dec 31, 2009-142.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2025Dec 31, 2025-165.4%−190.3
Q3 FY2025Sep 30, 2025-301.3%−147.7
Q2 FY2025Jun 30, 2025-372.2%−149.3
Q1 FY2025Mar 31, 2025-486.4%−316.4
Q4 FY2024Dec 31, 202424.9%+201.1
Q3 FY2024Sep 30, 2024-153.6%+36.2
Q2 FY2024Jun 30, 2024-222.9%+26.5
Q1 FY2024Mar 31, 2024-170.1%+464.4
Q4 FY2023Dec 31, 2023-176.2%+94.9
Q3 FY2023Sep 30, 2023-189.8%+60.1
Q2 FY2023Jun 30, 2023-249.4%+487.5
Q1 FY2023Mar 31, 2023-634.5%−270.4
Q4 FY2022Dec 31, 2022-271.0%+311.3
Q3 FY2022Sep 30, 2022-249.9%+270.5
Q2 FY2022Jun 30, 2022-736.9%−293.9
Q1 FY2022Mar 31, 2022-364.2%+155.8
Q4 FY2021Dec 31, 2021-582.4%−82.8
Q3 FY2021Sep 30, 2021-520.5%−158.9
Q2 FY2021Jun 30, 2021-443.1%−279.3
Q1 FY2021Mar 31, 2021-520.0%−245.9
Q4 FY2020Dec 31, 2020-499.5%−168.3
Q3 FY2020Sep 30, 2020-361.6%−24.1
Q2 FY2020Jun 30, 2020-163.8%+309.2
Q1 FY2020Mar 31, 2020-274.2%+149.7
Q4 FY2019Dec 31, 2019-331.2%−84.6
Q3 FY2019Sep 30, 2019-337.4%+8.9
Q2 FY2019Jun 30, 2019-473.0%−562.3
Q1 FY2019Mar 31, 2019-423.9%−171.9
Q4 FY2018Dec 31, 2018-246.6%−211.2
Q3 FY2018Sep 30, 2018-346.3%−386.1
Q2 FY2018Jun 30, 201889.3%+262.4
Q1 FY2018Mar 31, 2018-252.0%+6.3
Q4 FY2017Dec 31, 2017-35.4%+77.2
Q3 FY2017Sep 30, 201739.8%+158.8
Q2 FY2017Jun 30, 2017-173.1%−24.8
Q1 FY2017Mar 31, 2017-258.3%–
Q4 FY2016Dec 31, 2016-112.7%–
Q3 FY2016Sep 30, 2016-119.0%–
Q2 FY2016Jun 30, 2016-148.3%–

More Nektar Therapeutics figures

See a number that looks wrong?